# **Excision BioTherapeutics to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit**

## SAN FRANCISCO, Calif., July 21, 2020  / -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapeutics to cure viral infectious diseases, announced today that Daniel Dornbusch, CEO of Excision, will discuss the company’s gene therapy development programs at the B. Riley Virtual Infectious Disease Summit – Therapeutics Day on a Panel entitled “*Fast and Curious: Race to Finding Cures for Several Infectious Diseases, Including COVID-19*”. Excision will discuss its progressing pipeline including EBT-101, a multiplex Cas9 dual gRNA for HIV, EBT-103, a Cas9 triplet gRNA T-antigen for PML/JC Virus, EBT-104, a Cas9 dual gRNA for Herpes Simplex, and EBT-107 CasX dual gRNA for Hepatitis B.

**Date**: Tuesday, July 21, 2020

**Time**: 3:00 PM – 4:00 PM ET

**Excision BioTherapeutics**Daniel Dornbusch - Chief Executive Officer

**Weill Cornell Medicine/New York Presbyterian**Manuel Hidalgo, M.D. –Chief of the Division of Hematology and Medical Oncology

**Agenus Inc.**Jennifer Buell, Ph.D. – President and Chief Operating Officer

**Pluristem Therapeutics (PSTI)**Racheli Ofir – Vice President of Research & IP

**About Excision BioTherapeutics**

Excision BioTherapeutics Inc. is a biotechnology company developing therapies using CRISPR gene editing technology to cure patients of viral infectious diseases. Based on technologies from the Kamel Khalili, PhD lab at Temple University’s Lewis Katz School of Medicine and the Jennifer Doudna, PhD lab at the University of California Berkeley, the company is advancing CRISPR-based therapies for multiple viral infectious diseases with significant unmet medical needs. The company is supported by investments from Artis Ventures, Norwest Ventures, Abstract Ventures, SilverRidge Venture Partners, Oakhouse Partners, Gaingels, Elong Capital, and Ben Franklin Technology Partners.